An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(® )hydromorphone in patients with chronic cancer pain

BACKGROUND: Opioid analgesics have proven efficacy in the short-term management of chronic cancer pain, but data on their long-term use is more limited. OROS(® )hydromorphone is a controlled-release formulation of oral hydromorphone that may be particularly well suited to long-term management of chr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Magdi, Tuca, Alberto, Thipphawong, John
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753576/
https://www.ncbi.nlm.nih.gov/pubmed/19754935
http://dx.doi.org/10.1186/1472-684X-8-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753576/
https://www.ncbi.nlm.nih.gov/pubmed/19754935
http://dx.doi.org/10.1186/1472-684X-8-14

Ejemplares similares